<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02701634</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-406-1840</org_study_id>
    <secondary_id>2015-004572-30</secondary_id>
    <nct_id>NCT02701634</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination With Systemic Corticosteroids as First-Line Therapy in Subjects With Chronic Graft Versus Host Disease (cGVHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of entospletinib on the best overall response rate in
      adults with chronic graft versus host disease (cGVHD) who are currently receiving systemic
      corticosteroids as first-line therapy for cGVHD.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">May 27, 2016</start_date>
  <completion_date type="Actual">March 6, 2018</completion_date>
  <primary_completion_date type="Actual">December 19, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Overall Response Rate</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Best overall response rate by 24 weeks is defined as the proportion of participants who achieve a complete or partial overall response as assessed by the NIH cGVHD Activity Assessment (NCAA) within 24 weeks, in the setting of add-on therapy to systemic corticosteroids as part of first-line therapy for cGVHD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Skin Domain of the Lee Symptom Scale (LSS) at 24 Weeks</measure>
    <time_frame>Baseline; Week 24</time_frame>
    <description>The LSS is a patient-reported questionnaire used to measure symptom burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Mouth Domain of the LSS at 24 Weeks</measure>
    <time_frame>Baseline; Week 24</time_frame>
    <description>The LSS is a patient-reported questionnaire used to measure symptom burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Eyes Domain of the LSS at 24 Weeks</measure>
    <time_frame>Baseline; Week 24</time_frame>
    <description>The LSS is a patient-reported questionnaire used to measure symptom burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Total Score of the LSS at 24 Weeks</measure>
    <time_frame>Baseline; Week 24</time_frame>
    <description>The LSS is a patient-reported questionnaire used to measure symptom burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Duration of response is defined as the time from the documentation of best overall response rate to the documentation of progressive disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants who Achieve at Least 50% Reduction in Systemic Corticosteroid Dose Relative to Baseline</measure>
    <time_frame>Baseline; Week 24</time_frame>
    <description>The percentage reduction is calculated as (systemic corticosteroid dose at 24 weeks - baseline systemic corticosteroid dose) / baseline systemic corticosteroid dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants who Initiate Second-Line Therapy for cGVHD</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Second-line therapy for cGVHD is defined as receiving any therapy besides systemic corticosteroids or study drug for the treatment of cGVHD. Inhaled and topical steroids are not considered second-line therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure-free survival</measure>
    <time_frame>Up to 48 weeks</time_frame>
    <description>Failure-free survival is defined as the time from randomization to the earliest of first documentation of systemic therapy change, nonrelapse mortality, or recurrent malignancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants who Experience Any Adverse Events</measure>
    <time_frame>Up to 48 weeks plus 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants who Experienced Graded Laboratory Abnormalities</measure>
    <time_frame>Up to 48 weeks plus 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Chronic Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>Entospletinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Entospletinib for 48 weeks in combination with systemic corticosteroids as first-line therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match entospletinib for 48 weeks in combination with systemic corticosteroids as first-line therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open-Label Extension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After Week 48, all participants will have the option to receive entospletinib for an additional 96 weeks in the open-label extension phase, while continuing treatment with systemic corticosteroids as first-line therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entospletinib</intervention_name>
    <description>Entospletinib tablet(s) administered orally twice daily under fasted conditions</description>
    <arm_group_label>Entospletinib</arm_group_label>
    <arm_group_label>Open-Label Extension</arm_group_label>
    <other_name>GS-9973</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match entospletinib tablet(s) administered orally twice daily under fasted conditions</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Systemic Corticosteroids</intervention_name>
    <description>Systemic corticosteroids may include prednisone or prednisone equivalent.</description>
    <arm_group_label>Entospletinib</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Open-Label Extension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Willing and able to provide written informed consent

          -  Male or non-pregnant, non-lactating, females

          -  Newly diagnosed cGVHD defined by:

               -  At least 100 days after receiving any allogeneic hematopoietic stem cell
                  transplant AND

               -  Receiving a new course of systemic corticosteroids (≥ 0.5 mg/kg/day) as
                  first-line cGVHD therapy at least 1 day and no more than 21 days prior to first
                  dose of ENTO/Placebo AND

               -  Moderate to severe cGVHD as assessed by NIH cGVHD Diagnosis and Staging Criteria
                  (NCDSC) with at least three organ systems involved OR one organ system with a
                  score of 2 OR lung organ score = 1

          -  Individuals who have undergone transplant for hematologic malignancy are required to
             be in complete remission.

          -  Have either a normal ECG or one with abnormalities that are considered clinically
             insignificant by the investigator in consultation with the Sponsor

        Key Exclusion Criteria:

          -  Inability to begin systemic corticosteroids therapy at a dose of ≥ 0.5 mg/kg/day (or
             equivalent)

          -  Uncontrolled infection within 4 weeks prior to randomization

          -  History of the following therapies in the post-transplant period:

               -  B cell depleting biologic agents

               -  CD19 CAR-T cells based therapies

               -  BTK/SYK/JAK/PI3K inhibitors

               -  Phototherapy-unless administered for acute GVHD

          -  Treatment of cGVHD with anti-thymocyte globulins (ATG), or campath within 60 days of
             screening visit unless used for treatment of acute GVHD

          -  Severe organ dysfunction manifested during screening period:

               -  Requiring supplemental oxygen at more than 2 L/min

               -  Uncontrolled arrhythmia or heart failure

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taussig Cancer Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University, Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille, Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris Cedex 10</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Regensburg</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2016</study_first_submitted>
  <study_first_submitted_qc>March 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2016</study_first_posted>
  <last_update_submitted>May 12, 2018</last_update_submitted>
  <last_update_submitted_qc>May 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Graft Versus Host Disease (cGVHD)</keyword>
  <keyword>newly diagnosed cGVHD</keyword>
  <keyword>immune reconstitution</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>allogeneic stem cell transplantation</keyword>
  <keyword>SYK inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

